Jul 18, 2024
 in 
Hot Stocks 🔥

‘Strong Buy’ Sanofi To Expand In India | Nemo

Name of opportunity: 👀

Sanofi

Seems very healthy: 🩺

Yesterday, the French biopharmaceutical company Sanofi announced that it would be investing US$437.24 million by 2030 in its global capacity centre in Hyderabad, India. Already the largest of the company’s GCCs, the centre has 1000 staff currently, but the plan is to double this number. 

This a major sign of growth, and there have been other positive developments from Sanofi recently, getting investors interested in the healthcare company. Earlier this month, the company’s drug Dupixent, typically prescribed for asthma and eczema, was approved for use by adults with chronic obstructive pulmonary disease (COPD) in the EU. 

How hot is this investment opportunity? 🔥🔥🔥

Sanofi is currently recommended as a ‘Strong Buy’. Analysts predict the price of Sanofi will increase from $50.40 to $59.38 in the next 12 months. If you invested $1000, you might profit $182.53.

Reasons for this include Dupixent being approved for COPD in some countries, which will open up a new avenue of growth for the company. Sanofi is in ‘Above Average’ financial health, which puts it in a good position for future development. Analysts have also noted that the company’s pipeline of drugs in development looks promising, particularly drugs in the immunology segment. Sanofi has recently partnered with US company Novovax to launch a new COVID 19 vaccine, as well as to deliver a new combination flu and COVID vaccine, using technology from both companies. 

A dose of Sanofi: 💊

Sanofi is a multinational healthcare and pharmaceutical company with a presence in 100 countries around the world. It was founded in 1973 and is headquartered in Paris, France. More than 100,000 people are employed by Sanofi, which has 70 industrial plants and 20 R&D centres. Its seven areas of focus are: cardiovascular, central nervous system, diabetes, internal medicine, oncology, thrombosis, and vaccines. Sanofi Pasteur, the company’s vaccines division, is the largest company in the world devoted to vaccines. 

Which neme?: 🔍

<div class="install-nemo"><a data-property-value="Install Nemo" data-analytics="web_button_click" data-property-from="Blog" href="https://nemo-money.onelink.me/7Z9g/Hotstocks" target="_blank" class="nav-button green-to-yellow w-button">Install Nemo</a></div> 

Download Nemo to check out Sanofi

Han Tan

Han Tan is Chief Market Analyst at Nemo.money, bringing over a decade of experience in financial markets as both a seasoned journalist and analyst. Known for his sharp insights into stocks, currencies, and commodities, Han has become a familiar face to national audiences through appearances on Bloomberg TV Malaysia, BFM 89.9, and NTV7 — earning him a trusted reputation in financial media. Before joining Nemo, Han served as Market Analyst at Exinity Group from 2019, where his commentary on macroeconomic trends and market-moving news was regularly featured by global outlets including Reuters, Bloomberg, CNN, BBC, and AFP. Today, Han brings that same clarity and depth to Nemo’s community, delivering content-led ideas that empower first-time investors to confidently navigate global markets.